Crossmark

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Crossref DOI link: https://doi.org/10.1186/s13014-019-1420-z

Published Online: 2019-11-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Jingwen

Guan, Yun

Gu, Weilie

Yan, Senxiang

Zhou, Juying

Huang, Dan

Tong, Tong

Li, Chao

Cai, Sanjun

Zhang, Zhen

Zhu, Ji http://orcid.org/0000-0001-7134-9419
Funding

Funding for this research was provided by:

Natural Science Foundation of Shanghai (19ZR1410600)
License Information

Text and Data Mining valid from 2019-11-29

Version of Record valid from 2019-11-29
More Information

Article History

Received: 3 September 2019

Accepted: 14 November 2019

First Online: 29 November 2019

Ethics approval and consent to participate

: This study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. The trial protocol was approved by the Institutional Review Board on Medical Ethics at Fudan University Shanghai Cancer Center, and was registered at ClinicalTrials.gov (NCT 01064999). All study participants provided written informed consent prior to treatment.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below